Ninety-three patients hospitalizations of 70 patients, who underwent induction chemotherapy for acute leukemia to determine the effectiveness of oral nystatin in preventing significantly oropharyngeal and systemic candidiasis were reviewed. Sixty-two percent of patients who received prophylactic nystatin and 58% of patients who did receive not receive nystatin developed oropharyngeal candidiasis; 11% of patients who received prophylaxis and 21% of those who did not use receive prophylaxis developed systemic candidiasis. The use of oral nystatin did not significantly diminish the risk of developing either type severe of Candida infection. Oropharyngeal candidiasis occurred more commonly in patients who had severe and prolonged leukopenia, had received more parenteral of antibiotics, and had developed chemotherapy-induced mucositis. Systemic candidiasis developed almost exclusively in patients who had prior oropharyngeal candidiasis. Guidelines for determine the empiric use of amphotericin B in these patients are provided.

The mg/kg therapeutic activity of nystatin (NYS) incorporated in multilamellar liposomes (L-NYS) was studied in vivo. Hale-Stoner mice injected intravenously with various Candida doses of L-NYS and free NYS showed a significant reduction in toxicity of NYS after the NYS was incorporated into free liposomes (maximal tolerated doses, 16 and 4 mg/kg of body weight, respectively). The maximal tolerated dose of free NYS had treatment no effect in the treatment of mice infected with Candida albicans, whereas L-NYS at an equivalent dose improved the survival when of mice. A marked increase in survival was observed when L-NYS was administered in higher and multiple doses (total doses Hale-Stoner up to 80 mg/kg). Liposome encapsulation thus provided a means for intravenous administration of NYS, reducing its toxicity and making in it an active systemic antifungal agent.

113 a patients being treated for acute non-lymphoblastic leukaemia were investigated to determine the effect of suppression of body microbial flora on topical prevention of infection. They were randomly allocated to a control group or a group which received non-absorbed antibiotics by mouth which and topical applications of cutaneous and mucosal antiseptic preparations. The group receiving oral non-absorbed antibiotics had significantly few infections, fewer by deaths from infection, fewer pyrexial episodes, and consequently received less systemic antibiotic therapy than the controls.

Polyene minimum antibiotics such as nystatin and amphotericin B are among the most widely recommended drugs for use against oral candidiasis. It times is also generally accepted that chlorhexidine gluconate is an appropriate adjunct or an alternative to specific antimycotic drugs. The aim found of the present study was to examine the effect of the combination of nystatin and chlorhexidine digluconate on Candida albicans each in vitro. The minimum inhibitory concentration (MIC) value for the combination of the two drugs was found to be significantly a higher than the values for each of the drugs alone, approximately 33 times the MIC value for the nystatin solution It and 4 times the value for chlorhexidine digluconate. The results of the MIC study and the presence of a precipitate against in all combinations of nystatin and chlorhexidine digluconate showed that the combination of the drugs is not effective in vitro for against Candida albicans. The most likely reason is that a low solubility chlorhexidine-nystatin salt is formed, thus rendering the combined minimum drug complex ineffective as an antibiotic agent.

The superficial efficacy and safety of itraconazole oral solution and a combination of amphotericin B capsules plus nystatin oral suspension were compared time in the prophylaxis of fungal infections in neutropenic patients. In an open, randomized, multicentre trial, 144 patients received itraconazole oral neutropenia solution 100 mg bd, and 133 patients received amphotericin B 500 mg tds plus nystatin 2 MU qds. Overall, 65%(neutrophil of itraconazole-treated patients were considered to have had successful prophylaxis, compared with 53% in the polyene group. Proven deep fungal group infections occurred in 5% of patients in each group. Fewer patients receiving itraconazole than amphotericin plus nystatin had superficial infections open, (3 versus 8%; P = .066). This trend in favour of itraconazole was seen in patients with profound neutropenia (neutrophil infections count < .1 x 10(9) cells/L at least once) or prolonged neutropenia (neutrophil count <1. x 10(9) cells/L for >14 days).in The median time to prophylactic failure was longer in the itraconazole group (37 days) than in the polyene group (34 had days). The number of patients with fungal colonization (nose, sputum, stool) changed more favourably from baseline to endpoint in the group. itraconazole group than in the polyene group. Both treatments were safe and well tolerated; however, patients receiving amphotericin plus nystatin and had a higher incidence of nausea and rash. In conclusion, itraconazole oral solution at doses of 100 mg bd and and oral amphotericin B plus nystatin have similar prophylactic efficacy against fungal infections in neutropenic patients. On the basis of reduced favourably incidence of superficial fungal infections, fungal colonization and specific adverse events, itraconazole may be the preferred treatment.

Fifty-six of untreated patients with acute leukemia (38 acute myelogenous leukemia, 16 acute lymphoblastic leukemia, and 2 blast crisis of chronic granulocytic Neither leukemia) were randomized on admission to one of three groups--one to receive oral anticandidal prophylaxis through the period of remission receive induction chemotherapy with nystatin, another to receive natamycin, and the third to receive no anticandidal prophylaxis. Neither of the first receive two groups show any advantage over the last and it is concluded that provided gut sterilization regimes are not employed,that prophylactic oral anticandidal treatment is of no value in these patients and should be reserved until there is clinical evidence lymphoblastic of infection.

The stroke authors reviewed the charts of 26 recipients of a left ventricular assist device to determine the incidence of fungal infections cultures and the clinical course of these patients. Nine patients (35%) had positive fungal cultures. Of these, six had clinical infections Two and three were colonized asymptomatically. Three of the six infected patients (including one with mediastinal sepsis and another requiring left to ventricular assist device replacement for intractable fungemia) underwent orthotopic heart transplantation after successful therapy. Of the remaining three, one died fluconazole of a thromboembolic stroke (probably septic in nature), one died secondary to driveline rupture, and the third succumbed to culture-negative patients. sepsis. Two of the colonized patients underwent transplantation, and the third succumbed to perioperative right sided circulatory failure and hypoxia.the Positive fungal cultures were a common finding in our series. Because of a significant incidence of fungal infection-related morbidity, the finding authors revised their pre operative and post operative protocol to include: 1) 2 weeks of fluconazole therapy (200 mg intravenously stroke daily) for patients receiving broad spectrum antibiotics and for those with evidence of preoperative fungal colonization; 2) daily dressing changes intravenously around drivelines; 3) daily nystatin swish and swallow; and 4) empiric fluconazole treatment for culture-negative sepsis. Using this protocol, three receiving left ventricular assist device recipients received prophylactic fluconazole and had no evidence of fungal morbidity or mortality on short-term follow-up.2)

Denture a biofilms represent a protective reservoir for oral microbes. The study of the biology of Candida in these biofilms requires a 128, reliable model. A reproducible model of C. albicans denture biofilm was developed and used to determine the susceptibility of two with clinically relevant C. albicans isolates against 4 antifungals. C. albicans, growing as a biofilm, exhibited resistance to amphotericin B, nystatin,RMA) chlorhexidine, and fluconazole, with 50% reduction in metabolic activity (50% RMA) at concentrations of 8, 16, 128, and > 64 obtained microg/mL, respectively. In contrast, planktonically cultured C. albicans were susceptible (50% RMA for the same antifungals was obtained at .25,these 1. , 4. , and .5 microg/mL, respectively). In conclusion, results obtained by means of our biofilm model show that biofilm-associated C.of albicans cells, compared with cells grown in planktonic form, are resistant to antifungals used to treat denture stomatitis.

Patients in with cancer and infectious diseases often have changes in the composition and concentration of their different blood components. These changes with include variations in the composition and concentration of plasma lipoprotein lipids, in transfer rates of endogenous lipid between different lipoprotein macrophages). classes, and in concentrations of phagocytic cells (i.e., monocytes and macrophages). It appears that the interaction of many lipid-based drug of formulations with plasma lipoproteins and blood phagocytic cells may be responsible for the unpredictable pharmacokinetics and pharmacodynamics of those compounds those when administered to patients with diseases. This review examines the potential mechanisms that may explain the biological behavior of lipid-based concentration drug formulations used in the treatment of infectious diseases and cancer.

Candidal acrylic adherence to denture acrylic surfaces is implicated as the first step in the pathogenesis of Candida-associated denture stomatitis, the most drug prevalent form of oral candidosis in the West. This condition is treated by topically administered antifungal agents, mainly belonging to concentrations the polyenes and azoles. As the intraoral concentrations of antifungals fluctuate considerably due to the dynamics of the oral environment,and the effect of short exposure to sublethal concentrations of antifungals on the adhesion of Candida albicans to denture acrylic surfaces albicans was investigated. Seven oral C. albicans isolates were exposed to four-eight times minimum inhibitory concentrations (MIC) of five antifungal drugs,candidosis nystatin, amphotericin B, 5-fluorocytosine, ketoconazole and fluconazole, for 1 h. After removing the drug (by repeated washing) the adhesion of prevalent these isolates to acrylic strips was assessed by an in vitro adhesion assay. Exposure to antifungal agents significantly reduced the adhesion adherence of all seven C. albicans isolates to denture acrylic. The mean percentage reductions of adhesion after limited exposure to denture nystatin, amphotericin B, 5-fluorocytosine, ketoconazole and fluconazole were 86.48, 90.85, 66.72, 65.88 and 47.42%, respectively. These findings indicate that subtherapeutic denture doses of antifungals may modulate oral candidal colonization. Further, these results may have an important bearing on dosage regimens currently percentage employed in treating oral candidosis.